One-year results of a flexible regimen with ranibizumab therapy in macular degeneration: Relationship with the number of injections

Retina

Volumn 31, Issue 7, 2011, Pages 1261-1267

  Arias, Luis ^a   Roman, Isabel ^a   Masuet Aumatell, Cristina ^a   Rubio, Marcos J ^a   Caminal, Josep M ^a   Catala, Jaume ^a   Pujol, Octavio ^a  

^a HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

Author keywords

age related macular degeneration; choroidal neovascularization; flexible regimen; intravitreal ranibizumab

Indexed keywords

RANIBIZUMAB;

ADULT; AGED; ARTICLE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG SAFETY; FEMALE; FOLLOW UP; FOVEAVIRUS; HUMAN; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; PROSPECTIVE STUDY; RETINA MACULA AGE RELATED DEGENERATION; SUBRETINAL NEOVASCULARIZATION; THICKNESS; TREATMENT OUTCOME; VISUAL ACUITY;

AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, HUMANIZED; CHOROIDAL NEOVASCULARIZATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; INTRAVITREAL INJECTIONS; MACULAR DEGENERATION; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RETREATMENT; TOMOGRAPHY, OPTICAL COHERENCE; TREATMENT OUTCOME; VISUAL ACUITY;

EID: 79961210056     PISSN: 0275004X     EISSN: 15392864     Source Type: Journal    
DOI: 10.1097/IAE.0b013e318207d152     Document Type: Article

References (17)

1. Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006;355:1419-1431. (Pubitemid 44511557)
2. Brown DM, Kaiser PK, Michels M, et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 2006;355:1432-1444. (Pubitemid 44511558)
3. Regillo CD, Brown DM, Abraham P, et al. Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study year 1. Am J Ophthalmol 2008;145:239-248.
4. Ruiz-Moreno JM, Arias L, Armadá F, et al. Guías de práctica clínica de la SERV: Tratamiento de la degeneración macular asociada a la edad (DMAE) exudativa. Arch Soc Esp Oftalmol 2009;84:333-344.
5. Mitchell P, Korobelnik JF, Lanzetta P, et al. Ranibizumab (Lucentis) in neovascular age-related macular degeneration: evidence from clinical trials. Br J Ophthalmol 2010;94:2-13.
6. Arias L, Caminal JM, Casas L, et al. A study comparing two protocols of treatment with intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Br J Ophthalmol 2008;92:1636-1641.
7. Fung AE, Lalwani GA, Rosenfeld PJ, et al. An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration. Am J Ophthalmol 2007;143:566-583.
8. Lalwani GA, Rosenfeld PJ, Fung AE, et al. A variable-dosing regimen with intravitreal ranibizumab for neovascular agerelated macular degeneration: year 2 of the PrONTO study. Am J Ophthalmol 2009;148:43-58.
9. Spaide RF. Ranibizumab according to need: a treatment for age-related macular degeneration. Am J Ophthalmol 2007;143: 679-680.
10. Leung CK, Cheung CY, Weinreb RN, et al. Comparison of macular thickness measurements between time domain and spectral domain optical coherence tomography. Invest Ophthalmol Vis Sci 2008;49:4893-4897.
11. Gómez-Ulla F, Basauri E, Arias L, Martínez-Sanz F. Manejo de las inyecciones intravítreas. Arch Soc Esp Oftalmol 2009;84:377-388.
12. Cohen SY, Dubois L, Tadayoni R, et al. Results of one-year's treatment with ranibizumab for exudative age-related macular degeneration in a clinical setting. Am J Ophthalmol 2009;148: 409-413.
13. Dadgostar H, Ventura AA, Chung JY, Sharma S, Kaiser PK. Evaluation of injection frequency and visual acuity outcomes for ranibizumab monotherapy in exudative age-related macular degeneration. Ophthalmology 2009;116:1740-1747.
14. Rothenbuehler SP, Waeber D, Brinkmann CK, Wolf S, Wolf- Schnurrbusch UE. Effects on ranibizumab in patients with subfoveal choroidal neovascularization attributable to agerelated macular degeneration. Am J Ophthalmol 2009;147: 831-837.
15. Ahlers C, Golbaz I, Stock G, et al. Time course of morphologic effects on different retinal compartments after ranibizumab therapy in age-related macular degeneration. Ophthalmology 2008;115:e39-e46.
16. Spaide RF. The as-needed treatment strategy for choroidal neovascularization: a feedback-based treatment system. Am J Ophthalmol 2009;148:1-3.
17. Boyer DS, Antoszyk AN, Awh CC, Bhisitkul RB, Shapiro H, Acharya NR; MARINA Study Group. Subgroup analysis of the MARINA study of ranibizumab in neovascular age-related macular degeneration. Ophthalmology 2007;114:246-252. (Pubitemid 46172497)